Cytodyn Inc (CYDY)

[B52T38]

Question on S/C Mortality Data:

I know that no one at CYDY has access to the Phase 3 study data until it's unblinded, but I believe I have read that doctors and nurses can tell which patients were the likely recipients of LL based on individual lab results.

So my question is - if asked by CYDY employees, can these doctors/nurses reveal what they see re: individual lab results? In other words, while remaining "blind" to the actual LL/placebo patient lists, are there ways that CYDY employees can look at the individual labs and get a pretty good idea of who's getting better on LL and who is not?

This leads to my larger context question, namely - does our CYDY leadership have evidence-based reasons (from our current S/C trial) to be so upbeat about our upcoming trial results?